37 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly
8-K
EX-99.1
tp3ex8cccxw 97b
7 Nov 23
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
k3mrfdus6qf5zbomzgnj
16 Oct 23
Zymeworks Announces New Director Nominee
4:45pm
424B5
pljzp6m5yhuhr842m
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
7j7tve
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
2zx7t2mjeinjw3vxh
8 May 23
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:13pm
8-K
EX-99.1
c9mw l8a8v
18 Apr 23
ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles
4:18pm
DEF 14A
19r3tb6fw9df
25 Nov 22
Definitive proxy
6:16am